We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Targeted Breast Radiation Device Designed to Control Cancer

By HospiMedica International staff writers
Posted on 12 Aug 2010
A new study of breast cancer patients demonstrated that after nearly two years, the radiation given with a strut-adjusted volume implant (SAVI) controls the rate of cancer and may reduce the complications seen with alternate types of brachytherapy. More...
This study also demonstrates the accuracy and flexibility of the device to maximize the dose to the target tissue and minimize the exposure of healthy surrounding tissue and organs.

The study was conducted at Moores University of California, San Diego (UCSD) Cancer Center (USA) and the Arizona Oncology Services (Phoenix, USA). "This is the first paper that documents the patients' status after almost two years,” said Catheryn Yashar, M.D., associate professor of radiation oncology at the UCSD School of Medicine and chief of breast and gynecological radiation services at the Moores UCSD Cancer Center (USA). "After almost two years, the patients showed that the treatment was well-tolerated without experiencing significant side effects. To date, the control rate of cancer is also very promising.”

SAVI, which consists of comfortable, flexible catheters through which radiation is given, provides personalized radiation therapy and minimizes exposure to healthy tissue after a woman who has undergone a lumpectomy to remove a cancerous tumor. Radiation specialists sometimes choose to give women internal radiation a method called brachytherapy with the goal of giving concentrated doses of radiation to regions of concern while avoiding healthy tissue.

The study's findings, reported online June 18, 2010, in the International Journal of Radiation Oncology, Biology and Physics, revealed the results of 102 patients treated at a median follow-up time of 21 months. The researchers found that the SAVI appears to allow safely an increase in eligibility for patients to receive accelerated partial breast irradiation (APBI) over balloon brachytherapy or three-dimensional conformal radiation.

"This treatment allows us to provide internal radiation to the area without damaging the healthy tissue around the site, and minimizes radiation to a duration of only five days,” explained Dr. Yashar. "The traditional whole breast treatment usually takes approximately six weeks.”

The SAVI device was developed by Cianna Medical (Aliso Viejo, CA, USA).

Related Links:
Moores UCSD Cancer Center
Arizona Oncology Services
Cianna Medical


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Syringe Pump
SP50 Series
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.